Michael D. Grisham
Gründer bei Curate Biosciences
Aktive Beziehungen
Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
---|---|---|---|---|
David Backer | M | - |
Curate Biosciences
Curate Biosciences Miscellaneous Commercial ServicesCommercial Services Curate Biosciences engages in the development of a liquid biopsy platform for obtaining rare circulating tumor cells. It offers a desktop fluidic system for cell separation that pumps blood through a disposable microchip. The company was founded by Michael D. Grisham in 2002 and is headquartered in Richmond, VA. | - |
Daniel Getts | M | - |
Curate Biosciences
Curate Biosciences Miscellaneous Commercial ServicesCommercial Services Curate Biosciences engages in the development of a liquid biopsy platform for obtaining rare circulating tumor cells. It offers a desktop fluidic system for cell separation that pumps blood through a disposable microchip. The company was founded by Michael D. Grisham in 2002 and is headquartered in Richmond, VA. | 2 Jahre |
Mayo Pujols | M | 55 |
Curate Biosciences
Curate Biosciences Miscellaneous Commercial ServicesCommercial Services Curate Biosciences engages in the development of a liquid biopsy platform for obtaining rare circulating tumor cells. It offers a desktop fluidic system for cell separation that pumps blood through a disposable microchip. The company was founded by Michael D. Grisham in 2002 and is headquartered in Richmond, VA. | 2 Jahre |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
---|---|---|---|---|
Paul Billings | M | 71 |
Cellective Dx Corp.
Cellective Dx Corp. Pharmaceuticals: GenericHealth Technology Informed decisions will improve the way cancer is treated. On-Q-ity is an innovative diagnostic company that is focused on providing physicians with the tools they need to make the best decision when treating individual cancer patients. Its platform will enable better decision-making across multiple cancers: improving the cost of treatment, the quality of life for patients and ultimately increasing survival. Products currently in development are based on two core technologies: 1) DNA repair biomarkers that predict treatment response and 2) Microfluidic chip technology that enables capture, enumeration and characterization of circulating tumor cells (CTCs) in the bloodstream. | 1 Jahre |
Susan Siegel | F | 63 |
Cellective Dx Corp.
Cellective Dx Corp. Pharmaceuticals: GenericHealth Technology Informed decisions will improve the way cancer is treated. On-Q-ity is an innovative diagnostic company that is focused on providing physicians with the tools they need to make the best decision when treating individual cancer patients. Its platform will enable better decision-making across multiple cancers: improving the cost of treatment, the quality of life for patients and ultimately increasing survival. Products currently in development are based on two core technologies: 1) DNA repair biomarkers that predict treatment response and 2) Microfluidic chip technology that enables capture, enumeration and characterization of circulating tumor cells (CTCs) in the bloodstream. | - |
Ronald G. Tompkins | M | - |
Cellective Dx Corp.
Cellective Dx Corp. Pharmaceuticals: GenericHealth Technology Informed decisions will improve the way cancer is treated. On-Q-ity is an innovative diagnostic company that is focused on providing physicians with the tools they need to make the best decision when treating individual cancer patients. Its platform will enable better decision-making across multiple cancers: improving the cost of treatment, the quality of life for patients and ultimately increasing survival. Products currently in development are based on two core technologies: 1) DNA repair biomarkers that predict treatment response and 2) Microfluidic chip technology that enables capture, enumeration and characterization of circulating tumor cells (CTCs) in the bloodstream. | - |
Anne R. Kopf-Sill | M | - |
Cellective Dx Corp.
Cellective Dx Corp. Pharmaceuticals: GenericHealth Technology Informed decisions will improve the way cancer is treated. On-Q-ity is an innovative diagnostic company that is focused on providing physicians with the tools they need to make the best decision when treating individual cancer patients. Its platform will enable better decision-making across multiple cancers: improving the cost of treatment, the quality of life for patients and ultimately increasing survival. Products currently in development are based on two core technologies: 1) DNA repair biomarkers that predict treatment response and 2) Microfluidic chip technology that enables capture, enumeration and characterization of circulating tumor cells (CTCs) in the bloodstream. | - |
Lee Aurich | M | - |
Cellective Dx Corp.
Cellective Dx Corp. Pharmaceuticals: GenericHealth Technology Informed decisions will improve the way cancer is treated. On-Q-ity is an innovative diagnostic company that is focused on providing physicians with the tools they need to make the best decision when treating individual cancer patients. Its platform will enable better decision-making across multiple cancers: improving the cost of treatment, the quality of life for patients and ultimately increasing survival. Products currently in development are based on two core technologies: 1) DNA repair biomarkers that predict treatment response and 2) Microfluidic chip technology that enables capture, enumeration and characterization of circulating tumor cells (CTCs) in the bloodstream. | - |
Lena Wu | M | - |
Cellective Dx Corp.
Cellective Dx Corp. Pharmaceuticals: GenericHealth Technology Informed decisions will improve the way cancer is treated. On-Q-ity is an innovative diagnostic company that is focused on providing physicians with the tools they need to make the best decision when treating individual cancer patients. Its platform will enable better decision-making across multiple cancers: improving the cost of treatment, the quality of life for patients and ultimately increasing survival. Products currently in development are based on two core technologies: 1) DNA repair biomarkers that predict treatment response and 2) Microfluidic chip technology that enables capture, enumeration and characterization of circulating tumor cells (CTCs) in the bloodstream. | - |
Lou Dietz | M | - |
Cellective Dx Corp.
Cellective Dx Corp. Pharmaceuticals: GenericHealth Technology Informed decisions will improve the way cancer is treated. On-Q-ity is an innovative diagnostic company that is focused on providing physicians with the tools they need to make the best decision when treating individual cancer patients. Its platform will enable better decision-making across multiple cancers: improving the cost of treatment, the quality of life for patients and ultimately increasing survival. Products currently in development are based on two core technologies: 1) DNA repair biomarkers that predict treatment response and 2) Microfluidic chip technology that enables capture, enumeration and characterization of circulating tumor cells (CTCs) in the bloodstream. | - |
Statistik
Land | Beziehungen | % des Gesamten |
---|---|---|
Vereinigte Staaten | 10 | 100,00% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- Michael D. Grisham
- Persönliches Netzwerk